In early June, the same authority granted full reimbursement status for this orally available dual endothelin receptor antagonist. Tracleer(r) is being made available in Japan through Actelion’s own affiliate, with initially 35 territory managers focusing on hospital-based physicians.
Dr Jean-Paul Clozel CEO of Actelion, said: “With today’s launch in Japan, Actelion has realized its strategic goal of commercializing Tracleer(r) with its own infrastructure in all key pharmaceutical markets worldwide.
“We can now further leverage our worldwide capabilities in clinical development, regulatory affairs and marketing and sales with new innovative compounds from our own drug discovery efforts or, should the opportunity arise, from in-licensed or acquired drugs.”